Actively Recruiting
Adult and Adolescent Hemophilia Patients Treated With Marstacimab: a Patient Experience Registry
Led by Institute of Hematology & Blood Diseases Hospital, China · Updated on 2026-04-29
100
Participants Needed
2
Research Sites
150 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
Research Title：Adult and adolescent hemophilia patients treated with Marstacimab: a patient Experience Registry (AMBER) Protocol Number：94250855 Protocol Version Number：version 0.3 Date：15-November-2024 Leading site：Institution of Hematology \& Blood Diseases Hospital, Chinese Academy of Medical Sciences Active Pharmaceutical Ingredient：a human IgG1 monoclonal antibody that targets the tissue factor pathway inhibitor (TFPI) Drug Name Generic name: marstacimab-hncq Purpose of the Study Primary Objectives:To quantify patient preferences for subcutaneous versus intravenous (IV) injection using the Marstacimab-Patient Preference Questionnaire (M-PPQ) after 1 month of marstacimab for routine prophylaxis treatment. To assess the treatment burden using the Hemophilia Treatment Experience Measure (Hemo-TEM) in hemophilia patients after 6 months of marstacimab for routine prophylaxis treatment. Exploratory Objectives: To evaluate the annualized bleeding rate (ABR) of different types of bleeds after 6 months of subcutaneous marstacimab injections in hemophilia patients. To assess changes in joint status scores between baseline and the final visit after 6 months of subcutaneous marstacimab injections in hemophilia patients, using the Hemophilia Early Arthropathy Detection with Ultrasound in China (HEAD-US-C). To evaluate patient preferences regarding treatment experience via M-PPQ after 6 months
CONDITIONS
Official Title
Adult and Adolescent Hemophilia Patients Treated With Marstacimab: a Patient Experience Registry
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Diagnosed with hemophilia A or hemophilia B and eligible for prophylaxis treatment
- Prescribed marstacimab for routine prophylaxis by a clinical physician according to approved guidelines
- Aged 12 years or older (adolescents 12 to less than 18 years, adults 18 years and older)
- Signed informed consent provided by participant or legally authorized representative
You will not qualify if you...
- Unable to complete at least one month of follow-up as judged by the investigator
- Severe speech, vision, memory, or cognitive impairment affecting communication or ability to complete questionnaires and visits
- Women of childbearing age planning pregnancy within 2 months, pregnant, or breastfeeding
- Currently participating in other clinical trials
- Any other condition deemed unsuitable for participation by the investigator
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 2 locations
1
The First Affiliated Hospital of Xiamen University
Xiamen, Fujian, China
Actively Recruiting
2
Institute of haematology and Blood diseases hospital
Tianjin, Tianjin Municipality, China
Actively Recruiting
Research Team
R
renchi yang, MD
CONTACT
F
feng xue, MD
CONTACT
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
0
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here